摘要
血栓性疾病严重威胁着人类的生命健康。目前,临床治疗血栓性疾病以抑制凝血机制启动、阻断凝血酶活化为主要策略。利伐沙班作为一种新型口服抗凝药物,可以高效、准确地阻断血栓瀑布形成,具有靶向、低副作用、低出血风险的优势。随着利伐沙班的临床广泛使用,其对血小板(PLT)数量和功能的影响开始显现。文章就利伐沙班临床应用中引起的PLT计数和功能变化及其机制的相关研究进行综述,以期对用药期间患者凝血功能的合理评价提供参考。
Thrombotic disease seriously threatens human life and health,especially the normal function of cardiovascular and cerebrovascular diseases.The main strategy of treating thrombotic disease is to inhibit the initiation of coagulation mechanism and block thrombin activation.As a new oral anticoagulant,rivaroxaban can efficiently and accurately block thrombus waterfall formation,with targeting,low side effects and low bleeding risk,and it has been widely used in clinical practice recently.With the widespread clinical use of rivaroxaban,its effects on platelet(PLT)count and function begins to emerge.In this review,the changes in PLT count and function and the mechanism caused by rivaroxaban are summarized to facilitate the rational evaluation on the coagulation function of patients during medication.
作者
熊天慧
柴可宁
夏薇
曲林琳
XIONG Tianhui;CHAI Kening;XIA Wei;QU Linlin(Department of Clinical Laboratory,the First Hospital of Jilin University,Changchun 130021,Jilin,China;School of Medical Technology,Beihua University,Jilin 132013,Jilin,China)
出处
《检验医学》
CAS
2024年第5期504-509,共6页
Laboratory Medicine
基金
吉林省医疗卫生人才专项(JLSWSRCZX2021-049)。
